Fig 2: a There is a positive correlation between CSF C1q and NFL in subjects of all ages not currently receiving antiretroviral therapy (one outlier >3 SD removed). b There is a positive correlation between C1q and C3 in CSF. Correlations were analyzed using Spearman’s correlation coefficients

Fig 3: Association between IgG1–4, C3, C1q, cytokines and CHB patients with different treatment outcomes. (A) Forest plot of pre-treatment (baseline) levels of IgG1–4, C3, C1q, and cytokines in HBeAg-positve vs. HBeAg-negative; VR vs. PVR; SC vs. non-SC. (B) Post-treatment levels of the analytes in HBeAg-positve vs. HBeAg-negative; VR vs. PVR; SC vs. non-SC. Odd ratios were calculated using simple logistic regression models fitted with the outcome variables. The horizontal lines of each variable represent the 95% confidence interval of each odd ratio.

Fig 4: In 18–24 year-old youth, C1q was higher in cognitively impaired subjects compared to neurocognitively normal (NCN) subjects (median 2.13 versus 0.86ug/mL, p = 0.052)

Fig 5: Levels of IgG subtypes and complement C3 and C1q in serum of CHB patients with virological response (VR) and partial virological response (PVR) patients. Serum levels of IgG1–4, complement C3, and C1q were measured in VR patients (n = 70, purple dots) and PVR patients (n = 56, orange dots). Shaded areas indicate 95% confidence intervals around the regression lines. Bar graphs represent concentration of IgG1-4, complement C3 and C1q in pre-treatment (dark purple), post-treatment (light purple) of VR and pre-treatment (dark orange), post-treatment (light orange) of PVR patients. *p = 0.05, **p = 0.01, ***p = 0.001, ****p = 0.0001.